Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10302-10307

  Wang, Xianshu ^a   Wang, Fengwei ^a   Taniguchi, Ken ^a   Seelan, Ratnam S ^a   Wang, Liang ^a   Zarfas, Katherine E ^a   McDonnell, Shannon K ^a   Qian, Chiping ^a   Pan, Kaifeng ^c   Lu, Youyong ^c   Shridhar, Viji ^a   Couch, Fergus J ^a   Tindall, Donald J ^b   Beebe Dimmer, Jennifer L ^d   Cooney, Kathleen A ^d   Isaacs, William B ^e   Jacobsen, Steven J ^a   Schaid, Daniel J ^a   Thibodeau, Stephen N ^a   Liu, Wanguo ^a,f  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; PROTEIN P53; PROTEIN P53AIP1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER RISK; CELL GROWTH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DAMAGE; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DNA DAMAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATIC NEOPLASMS; RISK;

EID: 33751304472     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0638     Document Type: Article

References (23)

1. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(Spec No 1):R103-21.
2. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001;10:2313-8.
3. Mononen N, Syrjakoski K, Matikainen M, et al. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 2000;60:6479-81.
4. Ikonen T, Matikainen M, Mononen N, et al. Association of E-cadherin germline alterations with prostate cancer. Clin Cancer Res 2001;7:3465-71.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
6. Edwards SM, Kote-Jarai Z, Meitz J, et al. The Cancer Research UK/British Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1-12.
7. Cybulski C, Gorski B, Debniak T, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004;64:1215-9.
8. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003;72:270-80.
9. Cybulski C, Huzarski T, Gorski B, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004;64:2677-9.
10. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
11. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002;62:2883-9.
12. Wang L, McDonnell SK, Elkins DA, et al. Analysis of the RNASEL genes in familial and sporadic prostate cancer. Am J Hum Genet 2002;71:116-23.
13. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62:1425-38.
14. Wang L, McDonnell SK, Cunningham JM, et al. No association of germline alteration of MSRI with prostate cancer risk. Nat Genet 2003;35:128-9.
15. Berry R, Schroeder JJ, French AJ, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
16. Lange EM, Chen H, Brierley K, et al. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res 1999;5:4013-20.
17. Xu J, Zheng SL, Chang B, et al. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet 2001;108:335-45.
18. Melton LJ. 3rd History of the Rochester epidemiology project. Mayo Clin Proc 1996;71:266-74.
19. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.
20. Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res 1998;26:1396-400.
21. Wang X, Babu JR, Harden JM, et al. The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins. J Biol Chem 2001;276:26559-67.
22. Sasieni P. From genotypes to genes: doubling the sample size. Biometrics 1997;53:1253-61.
23. Slager S, Schaid D. Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet 2001;68:1457-62.